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A B S T R A C T
Purpose
Cancer and Leukemia Group B conducted a randomized phase II trial to investigate two novel
chemotherapy regimens in combination with concurrent thoracic radiation therapy (TRT).
Patients and Methods
Patients with unresectable stage III non–small-cell lung cancer (NSCLC) were randomly assigned
to carboplatin (area under the curve, 5) and pemetrexed (500 mg/m2) every 21 days for four cycles
and TRT (70 Gy; arm A) or the same treatment with cetuximab administered concurrent only with
TRT (arm B). Patients in both arms received up to four cycles of pemetrexed as consolidation
therapy. The primary end point was the 18-month overall survival (OS) rate; if the 18-month OS
rate was  55%, the regimen(s) would be considered for further study.
Results
Of the 101 eligible patients enrolled (48 in arm A and 53 in arm B), 60% were male; the median
age was 66 years (range, 32 to 81 years); 44% and 35% had adenocarcinoma and squamous
carcinoma, respectively; and more patients enrolled onto arm A compared with arm B had a
performance status of 0 (58% v 34%, respectively; P  .04). The 18-month OS rate was 58%
(95% CI, 46% to 74%) in arm A and 54% (95% CI, 42% to 70%) in arm B. No significant difference
in OS between patients with squamous and nonsquamous NSCLC was observed (P  .667). The
toxicities observed were consistent with toxicities associated with concurrent chemoradiotherapy.
Conclusion
The combination of pemetrexed, carboplatin, and TRT met the prespecified criteria for further
evaluation. This regimen should be studied further in patients with locally advanced unresectable
nonsquamous NSCLC.
J Clin Oncol 29:3120-3125. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Lung cancer is the leading cause of cancer-related
mortality in the United States for both men and
women, and 87% of lung cancers are non–small-cell
lung cancer (NSCLC).1,2 Approximately one third
of patients with NSCLC will present with unresect-
able stage III disease.3 Concurrent administration
of chemotherapy with thoracic radiation therapy
(TRT) is the standard of care for appropriate pa-
tients.4 The standard therapy used in this setting
involves systemic doses of cisplatin and etoposide
concurrent with TRT.5,6 It has been challenging to
administer systemically active doses of docetaxel,
gemcitabine, or vinorelbine in combination with
TRT.7-9 A novel chemotherapy regimen that could
be administered in systemically active doses yet
tolerable in combination with TRT would be of in-
terest because a majority of relapses after treatment
with concurrent chemotherapy and TRT are distant.
Pemetrexed was initially approved for the treatment
of metastatic NSCLC in the second-line setting10
and was subsequently approved for patients with
nonsquamous NSCLC as first-line and mainte-
nance therapy.11,12
Systemic doses of carboplatin and pemetrexed
and TRT were delivered with acceptable toxicities in
a phase I trial.13 Phase II studies in advanced NSCLC
suggested improved outcomes with the addition
of cetuximab, a monoclonal antibody against the
epidermal growth factor receptor, to platinum-
based chemotherapy.14-16 A phase III trial in patients
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with squamous cancer of the head and neck revealed a significant
improvement in overall survival (OS) with cetuximab and radia-
tion therapy compared with radiation therapy alone.17 Cancer and
Leukemia Group B (CALGB) conducted a randomized phase II
study (CALGB 30407) that incorporated [18F]fluorodeoxyglucose
(FDG) positron emission tomography (PET) staging before ther-
apy and three-dimensional conformal TRT with the intention of
developing a novel systemic therapy regimen to be used concur-
rent with TRT (ClinicalTrials.gov identifier: NCT00117962). We
elected to use carboplatin-based therapy because the phase I trial
and recent CALGB chemoradiotherapy trials have used carbopla-
tin, and we decided not to use any induction chemotherapy based
on our previous experience.13,18,19 The fact that pemetrexed is




Patients were required to have histologic or cytologic diagnosis of
NSCLC, inoperable stage IIIA or stage IIIB disease, measurable disease accord-
ing the Response Evaluation Criteria in Solid Tumors (RECIST),20 an Eastern
Cooperative Oncology Group performance status of 0 to 1, age  18 years, and
weight loss  10% in the past 3 months. Laboratory requirements were as
follows: an absolute neutrophil count (ANC) of  1,500/L, platelets
 100,000 L, a calculated creatinine clearance (CrCl) of  45 mL/min,
bilirubin 1.5 upper limit of normal (ULN), AST and ALT less than 3 ULN,
and alkaline phosphatase less than 3ULN. Patients were required to undergo
FDG-PET imaging, computed tomography (CT) scan of the chest and abdo-
men, and pulmonary function tests before enrollment. Patients were required
to have a mediastinal lymph node (LN) of  2 cm by CT scans; if the
mediastinal LN was less than 2 cm, then biopsy confirmation of malignant
involvement in mediastinal LN was required (regardless of the results of PET
imaging). Patients with contralateral mediastinal LN disease (N3) were eligible
if disease could be encompassed within a single radiation field. Patients with
scalene, supraclavicular, and contralateral hilar LN involvement based on
assessment of the treating physician; direct invasion of vertebral body; or
exudative, bloody, or cytologically malignant pleural effusions were not eligi-
ble. Prior chemotherapy for NSCLC, chest irradiation therapy, or therapy
directed at the epidermal growth factor receptor pathway was not allowed.
Patients who were pregnant or nursing; with known hypersensitivity to carbo-
platin, pemetrexed, or a monoclonal antibody; or who were HIV positive were
ineligible. This trial was approved by the institutional reviews boards of the
participating institutions, and patients were required to provide informed
consent before enrollment.
Chemotherapy Treatment Plan
The first 19 patients in arms A and B received carboplatin area under the
curve (AUC) of 6 using the Calvert equation21 over 30 minutes and pem-
etrexed 500 mg/m2 over 10 minutes every 21 days for four cycles. Patients
randomly assigned to arm B received cetuximab 400 mg/m2 over 120 minutes
on day 1 of week 1 and then 250 mg/m2 over 60 minutes weekly for 6 weeks
during the radiation therapy (for a total of 7 weeks). Radiation therapy started
on day 1 of therapy. After 19 patients had been treated, the trial was amended,
and the dose of carboplatin was reduced to an AUC of 5 because five patients
had experienced grade 4 thrombocytopenia. In the absence of disease progres-
sion or unacceptable toxicity, patients in both arms were treated with four
additional cycles of pemetrexed 500 mg/m2 administered every 21 days. Pa-
tients received folic acid, vitamin B12, and dexamethasone as recommended in
the pemetrexed package insert.22 Patients received diphenhydramine 50 mg
intravenously 30 to 60 minutes before the first dose of cetuximab, and dose
could be repeated before subsequent doses.
Patients received carboplatin and pemetrexed if the ANC was
 1,500/L and platelet count was  100,000/L; if ANC or platelet counts
were less than these levels, the treatment was held, and a CBC was checked on
a weekly basis. Febrile neutropenia resulted in a dose reduction of both agents.
Both agents were held for a CrCl of less than 45 mL/min, and if CrCl remained
less than 45 mL/min after 1 week, the protocol therapy was discontinued.
Patients who experienced a grade  3 infusion reaction as a result of carbopla-
tin were removed from protocol therapy. Patients who experienced grade  3
infusion reactions as a result of cetuximab discontinued cetuximab and con-
tinued other protocol therapy. Dermatologic toxicity related to cetuximab was
managed according to the package insert.23 For the consolidation therapy,
guidelines for dose adjustment were similar to those used during initial con-
current chemoradiotherapy. For patients experiencing radiation-related
esophagitis of grade  3, chemotherapy was held, patients were re-evaluated
on a weekly basis, and therapy was resumed when dysphagia had improved to
grade less than 3; carboplatin and pemetrexed were reduced one dose level for
subsequent cycles. Radiation was held for grade 4 esophagitis and then re-
sumed when dysphagia had improved to grade  2.
Radiation Treatment Plan
All patients were assigned to receive a cumulative dose of 70 Gy in 35
daily fractions of 2 Gy. Three-dimensional conformal TRT planning was
required, although the use of intensity-modulated radiotherapy was not al-
lowed. Photon beam energies of 4 to 25 MV could be used, and tissue hetero-
geneity factors were used for bone, soft tissue, and lung in dose calculations.
The gross tumor volume included the primary lung tumor on the planning CT
scan and staging FDG-PET, and LN metastases included LNs that were patho-
logically proven, were greater than 1.0 cm in short axis measurement on CT or
magnetic imaging, had a necrotic center, or demonstrated activity on FDG-
PET. PET imaging guidelines were included in the protocol, but determina-
tion of FDG-PET–active disease was left to the discretion of the treating
radiation oncologist, and a specific standardized uptake value cutoff point was
not specified. The clinical target volume included the primary tumor volume
and nodal volume with a 1.0-cm margin, except at the tumor/lung interface,
where a 0.5-cm margin was used. The planning target volume (PTV) included
the clinical target volume with a minimum margin of 0 to 0.5 cm and was
adjusted for respiration visualized under treatment simulation. Clinically un-
involved LNs were not targeted. A single PTV was used for the entire treatment
course, and the 95% isodense line was required to encompass the entire PTV.
Normal tissue constraints limited the volume of lung receiving 20 Gy to 40%
(calculated based on lung volume not involved with tumor), and the maxi-
mum spinal cord point dose allowed was 50 Gy. Specific esophageal dose
constraints were not mandated by protocol. Radiotherapy data, including
treatment planning CT images, portal images, and the three-dimensional data
set, were reviewed by Quality Assurance Review Center during the first week of
treatment, and a final review of all radiotherapy data was performed by the
radiotherapy study chair in conjunction with Quality Assurance Review Cen-
ter. The use of image-guided radiotherapy or respiratory gating was not spec-
ified. An analysis of the radiation treatment planning parameters and toxicity
is pending and will be published separately.
Efficacy and Toxicity Evaluation
The response was assessed according to RECIST after every two cycles
while on therapy; after completion of therapy, disease status was assessed every
4 months for 1 year, and then every 6 months for the next 2 years, and then
annually for the next 3 years. Toxicity assessments according to National
Cancer Institute Common Terminology Criteria for Adverse Events (version
3.0) were performed weekly for the first four cycles, and then every 3 weeks
during single-agent pemetrexed.
Statistical Methods
This was a single-stage randomized phase II trial with the primary objec-
tive of estimating the OS for patients treated with carboplatin and pemetrexed
with or without cetuximab in combination with TRT of 70 Gy. On the basis of
the estimated 18-month OS probability of 35% from the previous CALGB
trial, it was determined that if an 18-month OS probability of  35% was
observed, then the combination was not worthy of further investigation. If the
18-month OS probability was  55%, the combination would be worthy of
further investigation. Using a one-sided binomial exact test with a significance
level of P  .10, the study, with 50 patients in each arm, had 90% power to
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differentiate the hypotheses. The probability of erroneously concluding that
the treatment regimen was worthy of further investigation when the survival
probability was truly  35% was 0.071, and the probability of erroneously
concluding the treatment was not worthy of further investigation when the
survival probability was  55% was 0.078. The trial was not designed to have
adequate power to compare the two treatment arms.
OS is defined as the time from patient random assignment until death
from any cause. The Kaplan-Meier24 product-limit estimator was used to
estimate the median OS and the OS probability at 18 months, as well as the
95% CIs. A similar analytic method was used to characterize the failure-free
survival, which is the time between patient random assignment and a failure
event, defined as disease progression or death from any cause (whichever
occurred first). The proportion of patients who experienced a response (partial
or complete) to each combination was estimated, and binomial 95% CIs were
calculated. Toxicity was assessed for both combinations. For each type of
toxicity, a patient’s worst treatment-related toxic episode was used to summa-
rize distribution of toxicity grade experienced.
Patient registration and data collection were managed by the CALGB
Statistical Center. Data quality was ensured by careful review of data by
CALGB Statistical Center staff and by the study chairman. CALGB statisticians
performed statistical analyses.
As part of the quality assurance program of the CALGB, members of the
Audit Committee visit all participating institutions at least once every 3 years to
review source documents. The auditors verify compliance with federal regula-
tions and protocol requirements, including those pertaining to eligibility, treat-
ment, adverse events, tumor response, and outcome in a sample of protocols at
each institution. Such on-site review of medical records was performed for a
subgroup of 27 patients (25%) of the 109 patients enrolled onto this study.
RESULTS
Patients
The trial was activated in September 2005, and 109 patients were
registered between November 2005 and January 2008 (Fig 1). Of the
109 patients enrolled, six patients were cancelled before receiving any
protocol-related therapy as a result of myocardial infarction (n  1),
lack of adequate radiation planning equipment (n  1), physician
decision (n  1), and determination of ineligibility after enrollment
but before starting protocol therapy (n  3); two patients were found
to be ineligible after starting protocol therapy. The patient character-
istics are listed in Table 1. An imbalance in performance status was
observed between the two treatment arms.
Treatment Administration
Forty-eight patients initiated chemoradiotherapy in arm A, and
26 patients completed the eight cycles (Table 2). The most common
reasons for treatment discontinuation before completion in arm A
were adverse events (AEs; n10), disease progression (n5), patient
refusal (n  5), and death (n  1; Fig 1). Fifty-three patients initiated
chemoradiotherapy in arm B, and 28 patients completed the eight
cycles. The most common reasons for treatment discontinuation
before completion in arm B were AEs (n  10), disease progression
(n  6), patient refusal (n  4), and death (n  2). The median
three-dimensional conformal TRT for all patients with initiated radio-
therapy was 70 Gy (range, 10.53 to 76.92 Gy); 14 patients experienced
a radiation treatment interruption, and the median number of days of
treatment interruption was 2 (range, 1 to 9 days).
Toxicity
In arms A and B, 50 and 53 patients, respectively, were evaluable
for toxicity. The most common grade 3 and 4 hematologic AEs ob-
served in arms A and B are listed in Table 3. The common ( 10%)
grade 3 to 5 nonhematologic toxicities observed in arms A and B
(Table 3) were esophagitis, dysphagia, fatigue, pneumonitis, dehydra-
tion, and nausea/vomiting. The rates of observed grade 3 and 4 hema-
tologic AEs were 42% and 28%, respectively, in arm A and 38% and
32%, respectively, in arm B. No grade 5 hematologic AEs were ob-
served in either arm. The rates of observed grade 3 and 4 nonhemato-
logic AEs were 46% and 6%, respectively, in arm A and 53% and 9%,
Allocated to Arm A (n = 48)
Carboplatin + pemetrexed with 
TRT (70 Gy)
Completed four cycles
  carboplatin and pemetrexed (n = 44)
Completed 4 cycles of pemetrexed (n = 26)
Reasons for discontinuation:
  Completed eight cycles (n = 26)
)01 = n( stneve esrevdA  
)5 = n( lasufer tneitaP  
  Disease progression (n = 5)
)1 = n( htaeD  
)1 = n( rehtO  
Allocated to Arm B (n = 53)
Carboplatin, pemetrexed +
cetuximab with TRT (70 Gy)
Completed four cycles of carboplatin, 
  pemetrexed and cetuximab (n = 43)
Competed four cycles of pemetrexed (n = 28)
Reasons for discontinuation:
  Completed eight cycles (n = 28)
)01 = n( stneve esrevdA  
)4 = n( lasufer tneitaP  
  Disease progression (n = 6)
)2 = n( htaeD  




  Ineligible (n = 2)
  Cancelled prior to therapy (n = 6)
Assessed for eligibility
(N = 109)
Fig 1. CONSORT diagram. TRT, thoracic
radiation therapy.
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respectively, in arm B. Two patients in arm A experienced grade 5 AEs
(pulmonary hemorrhage and pneumonitis), and three patients in arm
B experienced grade 5 AEs (two experienced pneumonitis, and one
experienced grade 3 pneumonitis complicated by intrathoracic recur-
rence and pulmonary embolism leading to respiratory failure).
Efficacy
The efficacy data are listed in Table 4 and Appendix Table A1
(online only). With a median follow-up of 32 months (range, 11.7 to
48.4 months), 59 of 101 patients have died; the 18-month OS rates
observed in arms A and B were 58% (95% CI, 46% to 74%) and 54%
(95% CI, 42% to 70%), respectively (Table 4; Fig 2). The median
failure-free survival times observed in arms A and B were 12.6 months
(95% CI, 7.9 to 17.2 months) and 12.3 months (95% CI, 8.8 to 18.7
months), respectively (Fig 3).
An unplanned analysis of OS by histology revealed that among
patients with squamous and nonsquamous histology in both arms, the
median OS was 22.2 months (95% CI, 12.1 months to not available)
and 22.4 months (95% CI, 16.6 to 36.2 months), respectively; no
significant difference in OS between the squamous and nonsquamous
patients was observed (P  .667). The efficacy results of patients with
squamous and nonsquamous histology in treatment arms A and B are
listed in Table 5.
Of 101 patients, 59 patients have experienced progression. Four-
teen patients (24%) experienced local and distant progression, 19
patients (32%) experienced local disease progression alone, 26 pa-
tients (44%) experienced distant disease progression alone, and 12
patients developed brain metastases.
DISCUSSION
The OS observed in this study is significantly better than many of our
previous CALGB studies in patients with locally advanced unresect-
able NSCLC.18,25 It is tempting to attribute these results to the novel
chemotherapy regimen and higher doses of TRT, but a number of
others factors could have contributed to the results. The mandatory

















Male 27 56 24 64 61 60
Female 21 44 19 36 40 39
Age, years .74
Median 65 66 66
Range 41-79 32-81 32-81
Race .04
White 39 81 50 94 89 88
Black 8 17 2 4 10 10
Asian 0 0 1 2 1 1
Unknown 1 2 0 0 1 1
Histology .78
Adenocarcinoma 22 46 22 42 44 44
Squamous 17 35 18 34 35 35
NSCLC, undifferentiated 8 17 10 19 18 18
Large cell 0 0 2 4 2 2
Missing 1 2 1 2 2 2
Performance status .01
0 28 58 18 34 46 46
1 20 42 35 66 55 54
Stage .34
IIIA 29 60 27 51 56 55
IIIB 18 38 24 45 42 42
Missing 1 2 2 4 3 2
Abbreviation: NSCLC, non–small-cell lung cancer.
Table 2. Treatment Administration
Treatment
No. of Patients
Arm A: Carboplatin 
Pemetrexed
(n  48)




Completed all planned treatment 26 28
Chemoradiotherapy
Completed 1 cycle 1 3
Completed 2 cycles 2 5
Completed 3 cycles 1 2
Completed 4 cycles 44 43
Postchemoradiation chemotherapy
Completed 0 cycles 7 16
Completed 1 cycle 3 2
Completed 2 cycles 8 6
Completed 3 cycles 4 1
Completed 4 cycles 26 28
Table 3. Grade  3 Toxicities Observed on Cancer and Leukemia















Anemia 9 18 7 13
Neutropenia 21 42 25 47
Thrombocytopenia 18 36 18 34
Febrile neutropenia 4 8 3 6
Maximum hematologic 35 70 37 70
Nonhematologic toxicity
occurring at  10%
in one or both
treatment arms
Dehydration 6 12 5 9
Dysphagia 8 16 6 11
Dyspnea 5 10 3 6
Esophagitis 8 16 7 13
Fatigue 11 22 9 17
Hypokalemia 0 0 6 11
Nausea/vomiting 4 8 5 9
Pneumonitis 6 12 6 11
Rash (acneiform) 0 0 7 13
Maximum adverse events 38 76 45 85
Two treatment-related deaths were observed on arm A (one as a result of
pneumonitis and one as a result of pulmonary hemorrhage), and three were observed
on arm B (two as a result of pneumonitis and one as a result of grade 3 respiratory
toxicity complicated by pulmonary embolism and intrathoracic recurrence).
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use of FDG-PET scans for staging purposes and the exclusion of
patients with significant pretreatment weight loss may have contrib-
uted to the selection of patients with a better prognosis than those
enrolled in CALGB 39801. The use of a higher dose of TRT could have
contributed to the improved survival. The CALGB 30105 study of high-
dose TRT produced a median survival similar to CALGB 30407.19
The toxicities observed were similar to previous CALGB trials,
although rates of severe esophagitis were lower in this study presum-
ably related to absence of radiation to the uninvolved mediastinal
nodes.18 The fact that the efficacy of pemetrexed is limited to patients
with nonsquamous histology was not known when this study was
designed and conducted. The OS among patients with squamous and
nonsquamous histology was similar, but the number of patients in
each of the histologic subgroups was small, which reduced our ability
to detect an established treatment interaction. The ongoing inter-
national phase III study sponsored by Eli Lilly is investigating
pemetrexed and cisplatin in combination with TRT to 66 Gy com-
pared with cisplatin, etoposide, and TRT in patients with nonsqua-
mous NSCLC.26
In metastatic NSCLC, a phase III trial of cisplatin and vinorelbine
with or without cetuximab revealed an improvement in OS with the
addition of cetuximab.27 The addition of cetuximab to paclitaxel,
carboplatin, and radiation resulted in an encouraging median survival
of 23 months in a single-arm phase II study conducted by the Radia-
tion Therapy Oncology Group (RTOG).28 It is not clear whether the
observed improvement in survival (compared with prior RTOG stud-
ies) is a result of the addition of cetuximab or patient selection. We
would like to emphasize that CALGB 30407 was not designed to
compare the two different systemic therapy regimens (arm A without
cetuximab and arm B with cetuximab) but was designed only to
identify the arm(s) that would meet a predefined end point for further
exploration. Unlike arm A, arm B narrowly missed the predefined
criterion for further study. The ongoing RTOG phase III trial 0617 will
address the utility of cetuximab in addition to the role of an escalated
dose of TRT in the management of patients with unresectable stage
III NSCLC.
We should await the results of these two large trials before incor-
porating pemetrexed or cetuximab in routine clinical practice for the
treatment of patients with locally advanced NSCLC.
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Fig 2. Kaplan-Meier curve of overall survival by treatment arm.
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Fig 3. Kaplan-Meier curve of failure-free survival by treatment arm.















Complete response 4 8 2 4
Partial response 33 69 36 68
Stable response 11 23 12 23
Progressive disease 0 0 2 4
Not evaluable 0 0 1 2
Overall response rate, % 77 72
95% CI 63 to 88 58 to 83
Median failure-free survival,
months 12.6 12.3
95% CI 7.9 to 17.2 8.8 to 18.7
18-month failure-free survival, % 29 33
95% CI 19 to 45 23 to 49
Median overall survival, months 21.2 25.2
95% CI 17.5 to NA 14.4 to NA
18-month overall survival, % 58 54
95% CI 46 to 74 42 to 70
Abbreviation: NA, not available.
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